BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...formed Cullinan Florentine to develop CLN-049, an FLT3...
...– Fibroblast growth factor 21FLT3 (CD135) - FMS-like tyrosine kinase 3 BC...
BioCentury | Sep 3, 2020
Finance

Sept. 2 Quick Takes: Taysha files for IPO; plus DCVC’s Barclay joins Cohen’s Point72, Erasca, Deep Longevity and more

...received €4.5 million ($5.4 million) in series A financing led by V-Bio Ventures to develop FLT3...
...2014, the company counts Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. among its partners.TARGETSFLT3 (CD135) - FMS-like tyrosine kinase 3 BC...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting...
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...virus nuclear antigen 1 EGFR (ErbB1; HER1) - Epidermal growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3...
...CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho Ventures LLC Cullinan Oncology LLC Epstein-Barr virus nuclear antigen 1 (EBNA1) FMS-like tyrosine kinase 3...
...FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho Ventures LLC Cullinan Oncology LLC Epstein-Barr virus nuclear antigen 1 (EBNA1) FMS-like tyrosine kinase 3 (FLT3) (CD135) Epidermal...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | May 4, 2020
Deals

Stemline takeout gives Menarini U.S. oncology beachhead

...that could reach the U.S. market in the coming years. MEN1703, its dual inhibitor of FLT3...
...in the U.K., France, Spain, Germany or Italy following EU approval. Targets FLT3 (CD135) - FMS-like tyrosine kinase 3...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

...refractory settings, and most target molecularly-defined patient subgroups. Three of the newly approved agents target FLT3-mutated...
...another nine targeting this subgroup are in clinical testing, according to BioCentury's BCIQ database. The FLT3...
...cell factor (SCF) receptor tyrosine kinase CD33 (SIGLEC3) CD70 (CD27L) DNA methyltransferase FLT3 (CD135) - FMS-like tyrosine kinase 3...
BioCentury | Feb 12, 2020
Product Development

Freeline seeking ‘normal’ Factor IX activity via hemophilia gene therapy

Freeline has posted clinical potency data for its hemophilia B gene therapy that suggest its treatment could outperform its more advanced competitors. Chris Hollowood, Freeline Therapeutics Ltd. executive chairman and Syncona Ltd. chief investment officer,...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
Items per page:
1 - 10 of 691